Literature DB >> 26328106

How should prostate specific antigen be interpreted?

Ali Atan1, Özer Güzel1.   

Abstract

Since from its clinical introduction to the present time, measurement of serum prostate specific antigen (PSA) level is one of the most widely used tests in urology practice. Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years of age and younger. On the use of PSA as a screening test for prostate cancer, there are differences of opinion. However, it is a recommended test in the evaluation and monitoring of the risky group for prostate cancer. In conclusion PSA test should be performed at appropriate intervals for appropriate people with an appropriate age, after informing the patient about the test in detail.

Entities:  

Keywords:  Male; PSA; screening

Year:  2013        PMID: 26328106      PMCID: PMC4548626          DOI: 10.5152/tud.2013.038

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  44 in total

1.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

2.  Prostatic specific antigen and benign prostatic hyperplasia.

Authors:  A Atan; T Horn; F Hansen; H Jakobsen; T Hald
Journal:  Scand J Urol Nephrol       Date:  1996-08

3.  Is serum prostate-specific antigen level affected by fasting and nonfasting?

Authors:  Altug Tuncel; Hakan Aksut; Koray Agras; Umit Tekdogan; Kemal Ener; Ali Atan
Journal:  Urology       Date:  2005-07       Impact factor: 2.649

4.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

Review 5.  PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.

Authors:  Lionne D F Venderbos; Monique J Roobol
Journal:  Asian J Androl       Date:  2011-02-07       Impact factor: 3.285

6.  Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.

Authors:  C Mettlin; G P Murphy; F Lee; P J Littrup; A Chesley; R Babaian; R Badalament; R A Kane; F K Mostofi
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

Review 7.  Focal therapy for prostate cancer: pathologic basis.

Authors:  Vladimir Mouraviev; John F Madden
Journal:  Curr Opin Urol       Date:  2009-03       Impact factor: 2.309

8.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.

Authors:  Rune Kvåle; Anssi Auvinen; Hans-Olov Adami; Asa Klint; Eivor Hernes; Bjørn Møller; Eero Pukkala; Hans H Storm; Laufey Tryggvadottir; Steinar Tretli; Rolf Wahlqvist; Elisabete Weiderpass; Freddie Bray
Journal:  J Natl Cancer Inst       Date:  2007-12-11       Impact factor: 13.506

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

Review 10.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

View more
  4 in total

1.  Multiparametric prostatic MRI should not be the only method to decide re-biopsy in the patients who had a negative prostatic biopsy.

Authors:  Ali Atan
Journal:  Int Urol Nephrol       Date:  2019-07-09       Impact factor: 2.370

2.  Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population.

Authors:  Su Kang Kim; Hyun Kyung Park; Han Sung Choi; Koo Han Yoo; Joo-Ho Chung
Journal:  Int Neurourol J       Date:  2016-12-26       Impact factor: 2.835

3.  Breviscapine Participates in the Progression of Prostate Cancer by Inhibiting ZFP91 Expression through Upregulation of MicroRNA-129-5p.

Authors:  Jie Yang; Wanjun Jin; Xiaokang Zhang; Pengcheng Chang; Duo Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-08       Impact factor: 2.629

4.  Using Sigma metrics to establish analytical product performance requirements and optimize analytical performance of an in vitro diagnostic assay using a theoretical total PSA assay as an example.

Authors:  Victoria Petrides; Sharon Schneider
Journal:  Biochem Med (Zagreb)       Date:  2018-06-15       Impact factor: 2.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.